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Background. Increasing body mass index (BMI) is associated with increased risk of mortality; however, quantifying weight gain
in men undergoing androgen deprivation therapy (ADT) for prostate cancer (PC) remains unexplored. Methods. Between 1995
and 2001, 206 men were enrolled in a randomized trial evaluating the survival difference of adding 6 months of ADT to radiation
therapy (RT). BMI measurements were available in 171 men comprising the study cohort. The primary endpoint was weight gain
of ≥10lbs by 6-month followup. Logistic regression analysis was performed to assess whether baseline BMI or treatment received
was associated with this endpoint adjusting for known prognostic factors. Results. By the 6-month followup, 12 men gained ≥10lbs,
of which 10 (83%) received RT + ADT and, of these, 7 (70%) were obese at randomization. Men treated with RT as compared
to RT + ADT were less likely to gain ≥10lbs (adjusted odds ratio (AOR): 0.18 [95% CI: 0.04–0.89]; 𝑃 = 0.04), whereas this risk
increased with increasing BMI (AOR: 1.15 [95% CI: 1.01–1.31]; 𝑃 = 0.04). Conclusions. Consideration should be given to avoid ADT
in obese men with low- or favorable-intermediate risk PC where improved cancer control has not been observed, but shortened
life expectancy from weight gain is expected.
1. Introduction
The addition of androgen deprivation therapy (ADT) to
external beam radiation therapy (RT) has been shown to
prolong overall survival in men with intermediate or high-
risk prostate cancer (PC) enrolled on several randomized
controlled trials [1–7]. Despite this well-established survival
benefit, it is known that ADT has significant side effects that
adversely affect quality of life [3, 5, 8]. These side effects
include hot flashes, gynecomastia, decreased libido, nipple
sensitivity,anddecreasedmetabolism[9–14].Moreover,ADT
useinexcessof1yearhasalsobeenshowntoincreasetherisk
of osteoporosis [15, 16], diabetes [17–20], and cardiovascular
disease [18, 21, 22].
With regard to decreased metabolism, several investiga-
tors have shown that ADT causes a decrease in lean body
mass with a concomitant increase in total body fat of up to
∼10% [14, 16]. Of note, the increase in fat mass appears to
be distributed centrally about the abdominal compartment
[23]. Based on these findings, men are commonly advised
that weight gain is possible during ADT; however, the degree
to which weight gain occurs and risk factors associated with
weight gain are not well documented. Given the known
a s s o c i a t i o no fa ne l e v a t e dB M If o rm e nw h oa r eo v e r w e i g h t
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(BMI 25 to 29.9kg/m
2)o ro b e s e( B M I≥ 30kg/m
2)a n d
an increased risk of mortality [24], understanding weight
changes during ADT use is important when counseling men
about diet and exercise during ADT in order to minimize
weightgainandtherebyavoidincreasingtheriskofmortality.
Therefore, the purpose of this study was to use data from
a prospective randomized trial in order to ascertain clinical
factors at randomization associated with significant weight
gain (≥10 pounds) following the completion of RT and ADT
[3].Inaddition,wequantifiedweightgainacrossrandomized
treatment arms and within BMI categories as measured at
baselineinordertoquantifytheeffectofADTonweightgain
within each BMI category using the radiation-only arm as a
control.
2. Methods
2.1. Patient Population and Treatment. Between December 1,
1995, and April 15, 2001, 206 men were enrolled in a prospec-
tiverandomizedtrialevaluatingtheimpactonthesurvivalof
adding6monthsofcombinedADTto∼70GyRT[3].Priorto
randomization, patient age, prostate biopsy results, Gleason
score,serumprostate-specificantigenlevel(PSA),digitalrec-
tal exam findings (DRE), and adult comorbidity evaluation
27 (ACE-27) scores were ascertained and recorded. Of 206
men, 11 did not have a body mass index (BMI) measured
at randomization and 24 did not have BMI measured at the
endpoint, leaving 171 patients who formed the current study
c o h o r t .P a t i e n t sw e r er a n d o m i z e dt oR Ta l o n ec o n s i s t i n g
of 3-dimensional conformal RT to ∼70Gy or to the same
RT regimen with 2 months of neoadjuvant, concurrent, and
adjuvant combined ADT totaling 6 months and composed
ofaluteinizinghormone-releasinghormone(LHRH)agonist
and the antiandrogen flutamide. This secondary analysis of
the primary study was approved by the institutional review
board of the Dana-Farber/Harvard Cancer Center; informed
consent was obtained for the primary study. There is no
funding for this secondary analysis.
2.2. Assessment of Weight Gain at End of Treatment. Fol-
lowing the completion of RT with or without 6 months of
combined ADT, men were seen at approximately 6 months
after randomization. At each followup, a digital rectal exami-
nation, serum PSA, and weight measurement were obtained.
The scale used to measure patients at this 6-month followup
wasthesameasatrandomizationandthedifferenceinweight
in pounds was ascertained and recorded between the two
time-points.
2.3. Statistical Methods
2.3.1. Distribution and Comparison of Clinical Factors of
the Study Cohort Stratified by Randomized Treatment Arm.
Clinical characteristics at baseline were enumerated and
compared across randomized treatment arms. For the con-
tinuous covariates of BMI, PSA, and age, the nonparametric
Wilcoxon test [25, 26]w a su s e dt oc o m p a r et h ed i s t r i b u t i o n s
ofthesefactorsacrossrandomizedtreatmentarms.AMantel-
Haenszel chi-square metric [27, 28]w a su s e dt oc o m p a r et h e
distributionofcategoricalcovariatesincludinghighestbiopsy
Gleasonscore,2009AJCCtumor(T)category[29],andACE-
27 comorbidity score across randomized treatment arms.
2.3.2. Logistic Regression Analysis. The primary endpoint of
this study was whether the patient gained ≥10lbs by the 6-
month follow-up point after randomization. Univariable and
multivariable logistic regression [30]a n a l y s i sw a sp e r f o r m e d
to assess whether baseline BMI or treatment received was
associated with this endpoint adjusting for comorbidity and
known PC prognostic factors. Time zero was the date of
randomization. BMI, PSA, and age were treated as continu-
o u sc o v a r i a t e s ,wh e r e a st r e a t m e n ta r m ,G l e a so nsc o r e ,t u m o r
category, and ACE-27 score were considered as categorical
covariatesinthemodel.Thebaselinegroupforthecategorical
variables included the RT with ADT treatment arm, Gleason
score ≤ 6, tumor category 1 (T1), and ACE-27 with no
or minimal comorbidity, respectively. Adjusted odds ratios
and their associated 95% confidence intervals and 𝑃 values
were calculated. Two-sided 𝑃 values ≤ 0.05 were considered
statistically significant. SAS version 9.3 was used for all
statistical analyses.
2.3.3. Distribution of Weight Gain 6 Months following Ran-
domization, Stratified by Treatment Received and BMI. The
distribution of the 85 and 86 men, who underwent RT or RT
and ADT, respectively, and experienced ≥10lbs weight gain
versus <10lbs, 6 months following randomization, stratified
by well-defined BMI cut-points for normal weight, over-
weight,andobese,wascomparedusingFisher’sexacttest[31].
3. Results
3.1. Distribution and Comparison of Clinical Factors of the
Study Cohort Stratified by Randomized Treatment Arm.
Table 1 illustrates the distribution of clinical factors stratified
by randomized treatment arm (RT versus RT + ADT). As
expected,giventherandomization,allfactorsincludingBMI,
PSA, patient age, Gleason score distribution, and ACE-27
comorbidity score were not significantly different between
the two treatment arms (𝑃 value for each factor ≥ 0.11).
Of note, the median BMI and its distribution were nearly
equivalent between the two arms at baseline (27.44kg/m
2
[IQR = 25.58, 30.23] versus 27.35kg/m
2 [IQR = 24.68, 30.99];
𝑃 = 0.73).
3.2. Logistic Regression Analysis. By the 6-month followup,
12 men were observed to have gained ≥10lbs of which 10
(83%)weretreatedwithRTandADT,and7(70%)wereobese
at the time of randomization. For these 7 men, the median
increase in BMI was 5.21% (range: 3.60%–6.37%). As shown
in Table 2,m e nt r e a t e dw i t hR Ta sc o m p a r e dt oR Ta n dA D T
were significantly less likely to experience a weight gain of
≥10lbs (AOR: 0.18 [95% CI 0.04–0.89]; 𝑃 = 0.04), whereas
this risk was increased with increasing BMI (AOR: 1.15 [95%Prostate Cancer 3
Table 1: Distribution and comparison of clinical factors at randomization of the study cohort stratified by randomized treatment arm.
Clinical factor Treatment with RT
𝑁=8 5
Treatment with RT
and AST
𝑁=8 6
𝑃 value
Median BMI (IQR) 27.44kg/m
2
(25.58, 30.23)
27.35kg/m
2
(24.68, 30.99)
0.73
Median PSA (IQR) 11.54ng/mL
(7.70, 16.40)
10.85ng/mL
(7.50, 15.51)
0.38
Median Age (IQR) 73.36
(70.82, 76.15)
72.12
(69.07, 74.71)
0.11
T1 37 (44%) 46 (53%) 0.19
T2 48 (56%) 40 (47%)
Gleason score 6 or less 26 (31%) 25 (29%)
0.92 7 45 (53%) 49 (57%)
8t o1 0 14 (16%) 12 (14%)
No or minimal cm 65 (76%) 65 (76%) 0.89
Moderate to severe cm 20 (24%) 21 (24%)
RT indicates radiotherapy; ADT: androgen deprivation therapy; BMI: body mass index; IQR: interquartile range; PSA: prostate-specific antigen; cm:
comorbidity.
Table 2: Univariate and multivariate odds ratios for the risk of ≥10lbs weight gain 6 months after randomization for each clinical factor.
Clinical factor Number of men Number of men who
gained ≥10lbs by EOT
Univariable analysis Multivariable analysis
OR (95% CI) 𝑃 value AOR (95% CI) 𝑃 value
RT 85 2 0.18
(0.04, 0.86)
0.03 0.18
(0.04, 0.89)
0.04
RT + AST 86 10 1 (Ref) — 1( R e f) —
BMI increase per kg/m
2 171 12 1.18
(1.05, 1.33)
0.01 1.15
(1.01, 1.31)
0.04
P S Ai n c r e a s ep e rn g / m L 1 7 1 12 0.98
(0.90, 1.06)
0.58 0.97
(0.87, 1.08)
0.57
Age 171 12 0.93
(0.85, 1.02)
0.14 0.95
(0.85, 1.06)
0.38
Gleason score 8 to 10 26 3 2.09
(0.39, 11.15)
0.39 1.17
(0.17, 7.93)
0.87
79 4 6 1.091
(0.26, 4.56)
0.90 0.55
(0.10, 3.06)
0.49
6o rl e s s 5 1 31 ( R e f ) — 1( R e f) —
T2 88 8 1.98
(0.57, 6.82)
0.28 1.99
(0.49, 7.99)
0.33
T1 83 41 ( R e f ) — 1( r e f) —
Mod to Sev cm 41 5 2.44
(0.73, 8.15)
0.15 2.11
(0.54, 8.26)
0.28
No or min cm 130 71 ( R e f ) — 1( R e f) —
RT indicates radiotherapy; ADT: androgen deprivation therapy; BMI: body mass index; PSA: prostate-specific antigen; cm: comorbidity; OR: odds ratio; CI:
confidence interval; AOR: adjusted odds ratio; EOT: end of treatment.
CI 1.01–1.31]; 𝑃 = 0.04). No other clinical factors were found
to be significantly associated with this endpoint.
3.3. Distribution of Men Observed to Experience at Least a
10 Pound Weight Gain 6 Months following Randomization,
Stratified by Treatment Received and BMI Category. Table 3
illustrates the significant findings of the logistic regression
multivariable analysis. Specifically, men treated with RT and
ADTandwhowereobeseatrandomizationweresignificantly
morelikelytogain≥10lbsascomparedto<10lbsby6months
following randomization. These respective percentages were
70% versus 22%; 𝑃 = 0.006.H o w e v e r ,t h i ss i g n i fi c a n tt r e n d
was not noted for men who were obese at randomization
and underwent RT alone where the respective values were
0% and 28%; 𝑃 = 0.45.O fp a t i e n t sw i t han o r m a lB M I4 Prostate Cancer
Table 3: Distribution of weight gain 6 months following randomization, stratified by treatment received and body mass index.
RT only (𝑁=8 5 )R T + A D T ( 𝑁=8 6 )
Weight change 6 months following randomization
<10lbs (𝑁=8 3 ) ≥10lbs (𝑁=2 ) <10lbs (𝑁=7 6 ) ≥10lbs (𝑁=1 0 )
BMI (range in kg/m
2) (Range −13 to +9;
median −1lb)
(Range 10 to 13;
median +11.5lbs)
(Range −11 to +8;
median +1lb)
(Range 10 to 17lbs;
median +11.25lbs)
Normal (18.5–24.9) 17 (20%) 1 (50%) 22 (29%) 2 (20%)
Overweight (25.0–29.9) 43 (52%) 1 (50%) 37 (49%) 1 (10%)
Obese (≥30.0) 23 (28%) 0 (0%) 17 (22%) 7 (70%)
Fisher’s exact test 𝑃 value = 0.45 Fisher’s exact test 𝑃 value = 0.006
RT indicates radiotherapy; ADT: androgen deprivation therapy; BMI: body mass index.
at the time of enrollment, only 1 out of 18 men (6%) who
received RT alone and 2 out of 24 men (8%) who received
RT and ADT gained ≥10lbs (Fisher’s exact test, 𝑃 = 1.00),
suggesting no significant risk to normal-weight men of
becoming overweight from treatment with ADT.
4. Discussion
In this study, we observed that men at highest risk of ≥10lbs
weight gain following RT and 6 months of ADT were those
who were obese at the outset of treatment. Specifically, for
every 1 unit increase in BMI, there was a 15% increase in the
odds of gaining at least 10 pounds by the 6-month follow-up
visit and the median increase in BMI was 5.21%. Given the
establishedassociationofincreasedmortalitywithadditional
weight gain in obese men [24], these findings suggest that
some obese men may be at risk for a shortened survival
with ADT use. Therefore, the clinical significance of this
finding suggests taking a measured risk/benefit approach
when deciding on ADT use in obese men. In particular, this
consideration becomes extremely pertinent for obese men in
w h o mA D Tu s em a yh a v el i t t l eo rn oi m p a c to nr e d u c i n g
t h er i s ko fp r o s t a t ec a n c e r - s p e c i fi cm o r t a l i t y( P C S M )b u tc a n
s h o r t e nl i f ee x p e c t a n c y .
Several points require further clarification. First, weight
gain in obese patients is known to reduce both quality of life
(QoL) and longevity [24, 32, 33], in part due to increased risk
of cardiovascular events [34–36]a n dt h ese q u e l a eo fd i a be t e s
[37, 38]. Yet, there is no proven benefit for the use of ADT
in men with low risk PC despite its frequent use (up to 19%)
documented within a large observational database between
1 9 8 9a n d2 0 0 2( U C S FC a n c e ro ft h eP r o s t a t eS t r a t e g i c
Urologic Research Endeavor—CaPSURE) [39].
Specifically, ADT has been used in men with benign pro-
static hyperplasia and low risk PC who are not candidates for
brachytherapy due to pubic arch interference as determined
a tt h et i m eo fv o l u m es t u d y[ 40, 41]. In such men, ADT has
no proven benefit on reducing PCSM [5], but the results of
the current study show that ADT use can lead to significant
weightgaininmenwhoarealreadyobese,whichplacesthem
at higher risk of earlier morbidity and mortality because of
further increases in their BMI [13, 24, 33]. Second, recent
literature suggests that men with favorable-intermediate risk
prostate cancer [42] may not have a reduction in the risk
of PCSM from the addition of ADT to high dose RT [43].
Moreover, randomized controlled trials that have established
a survival benefit when ADT is added to RT in men with
unfavorable-intermediate or high-risk prostate cancer did
not have a prerandomization stratification by comorbidity,
andapostrandomizationanalysisbycomorbidityatrandom-
ization found no survival benefit for the addition of ADT to
RT [44]. Therefore, by applying similar reasoning,obese men
with favorable-intermediate risk PC may not benefit from
ADT use and may also be at risk for shortened survival and
decliningqualityoflife,withoutreductioninPSArecurrence,
metastasis, or death from PC from adding ADT to RT.
Therefore, ADT use should be discouraged in obese
men with low- or favorable-intermediate risk PC. Moreover,
future studies should employ a validated QoL metric [45]
and a measurement of PC-specific and overall survival in
obese men with unfavorable-intermediate and high-risk PC
to ascertain the risk/benefit ratio of adding ADT to RT in
obese men.
A limitation of the current analysis is the relatively small
event rate (𝑁=1 2 )o fa≥10lbs weight gain following
RT and 6 months of ADT. Therefore, validation of these
results by other investigators is needed. However, while the
overall event rate was small, the proportion of obese men
whoachievedthisendpointwassubstantialat70%.Moreover,
given that the proportion of men in the United States who
are obese and over the age of 50 is increasing [32], and with
the use of PSA screening, the proportion of men with low-
or favorable-intermediate risk PC has also been increasing
[46–48], and the potential negative impact of ADT use on
life expectancy would be expected to also increase if ADT
use is continued in these men. A strength of this study is
that the data are from a prospective randomized trial. As a
result,theradiationcontrolarmisavailableforcalculatingthe
increased odds of weight gain from the multivariable logistic
regression analysis for men who were randomized to receive
RTand6monthsofADT.Therefore,otherreasonsforweight
gain besides ADT use are controlled for by the study design,
lending additional support to both ADT and increasing BMI
being the drivers of the weight gains observed.
In conclusion, obese men are at increased risk for ≥10lbs
weight gain by the end of 6 months of ADT, prompting
serious consideration to limiting or avoiding the use of ADTProstate Cancer 5
in these men with low- or favorable-intermediate risk PC
where improvement in cancer control has not been observed
butashortenedlifeexpectancyfromfurtherweightgainmay
be expected.
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